INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, ...

Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Unlike conventional CAR-T, which carries a ~50% risk of cytokine release syndrome (CRS) and neurotoxicity, this novel therapeutic approach demonstrated complete absence of: Cytokine release syndrome ...

Targeting prostate-specific membrane antigen (PSMA) with a CD3 TCE could provide an effective treatment option for metastatic castration-resistant prostate cancer (mCRPC). In its poster ...

AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer Research Ⓡ (AACR) 116th Annual Meeting at ...

TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release ...

The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...